The interventions assessed were diverse, spanning pharmacological therapies (drotrecogin alfa, recombinant human activated protein C, angiotensin II, hydrocortisone), infection prevention strategies (probiotics, closed infusion containers, multilayer silicone dressings, hand hygiene), and organizational or protocol-driven approaches (quality improvement programs, sepsis management protocols, prolonged ICU care vs. early withdrawal of support, or monitoring with pulmonary artery catheters). This evidence concerns the gene AGT and Sepsis.